Literature DB >> 20349049

Cannabis constituents modulate δ9-tetrahydrocannabinol-induced hyperphagia in rats.

Jonathan A Farrimond1, Andrew J Hill, Benjamin J Whalley, Claire M Williams.   

Abstract

RATIONALE: The hyperphagic effect of Delta9-tetrahydrocannabinol (Delta9THC) in humans and rodents is well known. However, no studies have investigated the importance of Delta9THC composition and any influence other non-Delta9THC cannabinoids present in Cannabis sativa may have. We therefore compared the effects of purified Delta9THC, synthetic Delta9THC (dronabinol), and Delta9THC botanical drug substance (Delta9THC-BDS), a Delta9THC-rich standardized extract comparable in composition to recreationally used cannabis.
METHODS: Adult male rats were orally dosed with purified Delta9THC, synthetic Delta9THC, or Delta9THC-BDS, matched for Delta9THC content (0.34-2.68 mg/kg). Prior to dosing, subjects were satiated, and food intake was recorded following Delta9THC administration. Data were then analyzed in terms of hourly intake and meal patterns.
RESULTS: All three Delta9THC substances tested induced significant hyperphagic effects at doses >or=0.67 mg/kg. These effects included increased intake during hour one, a shorter latency to onset of feeding and a greater duration and consumption in the first meal. However, while some differences in vehicle control intakes were observed, there were significant, albeit subtle, differences in pattern of effects between the purified Delta9THC and Delta9THC-BDS.
CONCLUSION: All Delta9THC compounds displayed classical Delta9THC effects on feeding, significantly increasing shortterm intake whilst decreasing latency to the first meal. We propose that the subtle adjustment to the meal patterns seen between the purified Delta9THC and Delta9THC-BDS are due to non-Delta9THC cannabinoids present in Delta9THC-BDS. These compounds and other non-cannabinoids have an emerging and diverse pharmacology and can modulate Delta9THC-induced hyperphagia, making them worth further investigation for their therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20349049     DOI: 10.1007/s00213-010-1821-z

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  42 in total

1.  End of the line for cannabinoid receptor 1 as an anti-obesity target?

Authors:  Dan Jones
Journal:  Nat Rev Drug Discov       Date:  2008-12       Impact factor: 84.694

2.  Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.

Authors:  Adèle Thomas; Lesley A Stevenson; Kerrie N Wease; Martin R Price; Gemma Baillie; Ruth A Ross; Roger G Pertwee
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

Review 3.  Cannabinoids in clinical practice.

Authors:  E M Williamson; F J Evans
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

4.  Observational analysis of feeding induced by Delta9-THC and anandamide.

Authors:  Claire M Williams; Tim C Kirkham
Journal:  Physiol Behav       Date:  2002-06-01

5.  A novel component of cannabis extract potentiates excitatory synaptic transmission in rat olfactory cortex in vitro.

Authors:  Benjamin J Whalley; Jonathan D Wilkinson; Elizabeth M Williamson; Andrew Constanti
Journal:  Neurosci Lett       Date:  2004-07-15       Impact factor: 3.046

6.  Cannabidiol targets mitochondria to regulate intracellular Ca2+ levels.

Authors:  Duncan Ryan; Alison J Drysdale; Carlos Lafourcade; Roger G Pertwee; Bettina Platt
Journal:  J Neurosci       Date:  2009-02-18       Impact factor: 6.167

Review 7.  Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.

Authors:  Theresa H M Moore; Stanley Zammit; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis
Journal:  Lancet       Date:  2007-07-28       Impact factor: 79.321

Review 8.  Dual modulation of CNS voltage-gated calcium channels by cannabinoids: Focus on CB1 receptor-independent effects.

Authors:  Natalia Lozovaya; Rogier Min; Vera Tsintsadze; Nail Burnashev
Journal:  Cell Calcium       Date:  2009-08-13       Impact factor: 6.817

9.  The phytocannabinoid Delta(9)-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum.

Authors:  Y-L Ma; S E Weston; B J Whalley; G J Stephens
Journal:  Br J Pharmacol       Date:  2008-03-03       Impact factor: 8.739

10.  Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study.

Authors:  M Herkenham; A B Lynn; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  J Neurosci       Date:  1991-02       Impact factor: 6.167

View more
  6 in total

1.  Neuromotor tolerability and behavioural characterisation of cannabidiolic acid, a phytocannabinoid with therapeutic potential for anticipatory nausea.

Authors:  Daniel I Brierley; James Samuels; Marnie Duncan; Benjamin J Whalley; Claire M Williams
Journal:  Psychopharmacology (Berl)       Date:  2015-10-06       Impact factor: 4.530

2.  Cannabinol and cannabidiol exert opposing effects on rat feeding patterns.

Authors:  Jonathan A Farrimond; Benjamin J Whalley; Claire M Williams
Journal:  Psychopharmacology (Berl)       Date:  2012-04-28       Impact factor: 4.530

Review 3.  Translational models of cannabinoid vapor exposure in laboratory animals.

Authors:  Catherine F Moore; Jeffrey W Stiltner; Catherine M Davis; Elise M Weerts
Journal:  Behav Pharmacol       Date:  2022-04-01       Impact factor: 2.293

4.  Chemotherapy-induced cachexia dysregulates hypothalamic and systemic lipoamines and is attenuated by cannabigerol.

Authors:  Daniel I Brierley; Joe R Harman; Natasha Giallourou; Emma Leishman; Anna Emily Roashan; Ben A D Mellows; Heather B Bradshaw; Jonathan R Swann; Ketan Patel; Benjamin J Whalley; Claire M Williams
Journal:  J Cachexia Sarcopenia Muscle       Date:  2019-04-29       Impact factor: 12.910

Review 5.  Phytocannabinoids-A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment.

Authors:  Klaudia Berk; Wiktor Bzdega; Karolina Konstantynowicz-Nowicka; Tomasz Charytoniuk; Hubert Zywno; Adrian Chabowski
Journal:  J Clin Med       Date:  2021-01-20       Impact factor: 4.241

6.  Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats.

Authors:  Daniel I Brierley; James Samuels; Marnie Duncan; Benjamin J Whalley; Claire M Williams
Journal:  Psychopharmacology (Berl)       Date:  2016-08-09       Impact factor: 4.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.